Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 2807-2813

  Platz, Elizabeth A ^a   Till, Cathee ^b   Goodman, Phyllis J ^b   Parnes, Howard L ^c   Figg, William D ^c   Albanes, Demetrius ^c   Neuhouser, Marian L ^d   Klein, Eric A ^e   Thompson Jr , Ian M ^f   Kristal, Alan R ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RISK REDUCTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLESTEROL; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 72749105394     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0472     Document Type: Article

References (30)

1. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825 (Pubitemid 46017933)
2. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-2217 (Pubitemid 351196351)
3. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-2232 (Pubitemid 351196353)
4. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-2225
5. Friedman GD, Flick ED, Udaltsova N, Chan Pharm DJ, Quesenberry CP, Jr., Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36. (Pubitemid 351166615)
6. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-219
7. Boudreau DM, Yu O, Buist DS, Miglioretti DL. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008;19:767-774
8. Platz EA. Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 2175-2180 (Pubitemid 351196344)
9. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-325 (Pubitemid 41389713)
10. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
11. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008; 123:1693-1698
12. Morris DL, Borhani NO, Fitzsimons E, et al. Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer 1983;52:1754-1759
13. Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 1988;41:519-530 (Pubitemid 18158824)
14. Schatzkin A, Hoover R, Taylor P, et al. Site-specific analysis of total serum cholesterol and incidence cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 1988;48:452-458 (Pubitemid 18045786)
15. Schuit AJ, Van Dijk CE, Dekker JM, Schouten EG, Kok FJ. Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol 1993;137:966-976
16. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997;6:863-873 (Pubitemid 27481633)
17. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2000;71:569-574 (Pubitemid 30061238)
18. Wuermli L, Joerger M, Henz S, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8: 316-320 (Pubitemid 43078165)
19. Thompson I, Goodman P, Tangen C, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224 (Pubitemid 36859473)
20. Goodman PJ, Tangen CM, Crowley JJ, et al. Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 2004;25: 203-222 (Pubitemid 38328759)
21. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374 (Pubitemid 24037911)
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): National Health, Lung, and Blood Institute, National Institutes of Health; 2002. Report No.: NIH Publication No. 02-5215.
23. Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008;19:113-121
24. Thompson MM, Garland C, Barrett-Connor E, Khaw KT, Friedlander NJ, Wingard DL. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989;129:511-517 (Pubitemid 19069073)
25. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse, and physical activity. Cancer Epidemiol Biomarkers Prev 1995; 4:807-811
26. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-1133 (Pubitemid 44288787)
27. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-1752 (Pubitemid 46560657)
28. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-1383 (Pubitemid 351767184)
29. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostate Dis 1998;1:157-162 (Pubitemid 128545860)
30. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-1781